Loading BSD 13F portfolios...
Elite Manager Tracking
The Top 150 BSDs
Real-time 13F holding analysis for the industry's most influential institutional investors. Track conviction shifts, new entries, and structural exits.
Real-time 13F holding analysis for the industry's most influential institutional investors. Track conviction shifts, new entries, and structural exits.

Institutional Investor • EcoR1 Capital
Value
$2.2B
Stocks
26 Stocks
Turnover
0.0%
Top Holdings
ZYME(32.10%) ANAB(28.43%) AKTS(8.31%) ETON(4.20%) CRSP(4.05%)
Investment philosophy details pending verification.
| Ticker | P/C | Company Name | Sector | Market Value | Shares | Weight | Chg Shares | % Chg |
|---|---|---|---|---|---|---|---|---|
| ZYME | None | ZYMEWORKS INC | General | $600.4M | 0 | 32.1% | 0 | No Change |
| ANAB | None | AnaptysBio Inc | Health Care | $531.9M | 0 | 28.4% | 0 | No Change |
| AKTS | None | AKOUSTIS TECHNOLOGIES INC | General | $155.5M | 0 | 8.3% | 0 | No Change |
| ETON | None | ETON PHARMACEUTICALS INC | General | $78.6M | 0 | 4.2% | 0 | No Change |
| CRSP | None | CRISPR Therapeutics | Health Care | $75.8M | 0 | 4.0% | 0 | No Change |
| ORIC | None | ORIC PHARMACEUTICALS INC | General | $72.9M | 0 | 3.9% | 0 | No Change |
| TRAX | None | First Tracks Biotherapeutics | General | $63.9M | 0 | 3.4% | 0 | No Change |
| NGNE | None | NEUROGENE INC | General | $40.0M | 0 | 2.1% | 0 | No Change |
| CGON | None | CG Oncology, Inc. | Healthcare | $39.9M | 0 | 2.1% | 0 | No Change |
| STOK | None | Stoke Therapeutics, Inc. | General | $24.0M | 0 | 1.3% | 0 | No Change |
| Ticker | Amount | % Chg | Weight | Status |
|---|---|---|---|---|
| No recent buys. | ||||
| Ticker | Amount | % Chg | Weight | Status |
|---|---|---|---|---|
| No recent sells. | ||||
| Sector | Stocks | Value | Exposure |
|---|---|---|---|
| General | 20 | $1179.6M | 63.1% |
| Health Care | 5 | $651.1M | 34.8% |
| Healthcare | 1 | $39.9M | 2.1% |